Clinical Trials Browser

Phase 2 × INDUSTRY × lorlatinib × Clear all

NCT05297890 2025-12-23

A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer

NCT03909971 2025-11-05

A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Phase 2 Completed

109 enrolled 33 charts

Carcinoma, Non-Small-Cell Lung